Relmada Therapeutics, Inc. Common Stock

RLMDNASDAQ • USD
3.46 USD
↘ 0.76 (17.90%)🟢LIVE (AS OF 01:57 PM EST)
🟢Market: OPEN

Shares of Relmada Therapeutics, Inc. Common Stock (RLMD) are trading at $3.46. Our models show a "Buy" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation side, RLMD appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Nov 13, 2026.

Open?$4.11
High?$4.22
Low?$3.46
Prev. Close?$4.21
Volume?1.2M
Avg. Volume?1.6M
VWAP?$3.66
Rel. Volume?0.73x
Bid / Ask
Bid?$3.53 × 900
Ask?$3.54 × 600
Spread?$0.01
Midpoint?$3.54
Valuation & Ratios
Market Cap?449.2M
Shares Out?106.7M
Float?86.9M
Float %?81.5%
P/E Ratio?N/A
P/B Ratio?2.32
EPS?-$0.62
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Employees
17
Market Cap
449.2M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2014-03-03
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR
CORAL GABLES, FL 33134
Phone: 646 876 3459
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
59
Piotroski F-Score?0/9Weak
Altman Z-Score?18.30Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?12.47%High
Short Interest?10.8M
Days to Cover?6.4
Free Float86.9M
Avg Daily Volume1.7M
Settlement Date2026-10-30
Financial Health
Current Ratio?26.37Strong
Quick Ratio?26.37Strong
Cash Ratio?0.74Adequate
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
68
2.32CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.5CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
5
-33.9%WEAK▾
ROA?
S&P
3
-32.0%WEAK▾
Cash Flow & Enterprise
FCF?$-51855449
Enterprise Value?$443.5M
Fundamentals ratios updated end of day